Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29555 | 0.81 | GRIN1 (0.43) | GRIN1GRIN2BSLC6A4GPR6TRPA1 | |
| SCHEMBL26933609 | 0.79 | GRIN1 (0.45) | GRIN1GRIN2BALDH1A1TRPA1 | |
| SCHEMBL26933616 | 0.79 | GRIN1 (0.45) | GRIN1GRIN2BALDH1A1TRPA1 | |
| Hydrochloric Acid SCHEMBL30636301 | 0.77 | GRIN1 (0.44) | GRIN1GRIN2BTRPA1 | |
| SCHEMBL941030 | 0.77 | SLC6A2 (0.58) | SLC6A4 | |
| SCHEMBL26144164 | 0.76 | CSNK2A1 (0.41) | GRIN1GRIN2BGPR6 | |
| SCHEMBL2299176 | 0.76 | GRIN1 (0.40) | GRIN1GRIN2BGPR6TRPA1 | |
| SCHEMBL14956969 | 0.76 | SLC6A4 (0.59) | SLC6A4 | |
| Hydrochloric Acid SCHEMBL2778482 | 0.76 | SLC6A2 (0.56) | SLC6A4 | |
| Hydrochloric Acid SCHEMBL30357915 | 0.75 | SLC6A4 (0.57) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154173-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2025096697-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154173-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | GRIN1 579/4885GRIN2B 2105/4885SLC6A4 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.